1. Approach to a Patient with Peritoneal Metastases with Unknown Primary Site: Focus on Histopathological Evaluation
   Aditi Bhatt et al, 2020, Pathology of Peritoneal Metastases CrossRef
2. Global miRNA/proteomic analyses identify miRNAs at 14q32 and 3p21, which contribute to features of chronic iron-exposed fallopian tube epithelial cells
   Ravneet Chhabra et al, 2021, Scientific Reports CrossRef
3. A Case Report of Pseudomyxoma Peritonei Arising From Primary Mucinous Ovarian Neoplasms
   Reuben Joseph et al, 2022, Cureus CrossRef
4. Histopathological Evaluation and Molecular Diagnostic Tests for Peritoneal Metastases with Unknown Primary Site—a Review
   Aditi Bhatt et al, 2023, Indian Journal of Surgical Oncology CrossRef
5. Paired-Box Gene 8 (PAX8) and Its Association With Epithelial Carcinomas
   Khalid Khizer et al, 2021, Cureus CrossRef
6. MACC1-AS1 promotes hepatocellular carcinoma cell invasion and proliferation by regulating PAX8
   Hui Tong et al, 2020, Aging CrossRef
7. Cytopathological assessment is an accurate method for identifying immunophenotypic features and BRCA1/2 mutations of high‐grade serous carcinoma from ascites
   Simona Miceska et al, 2023, Cancer Cytopathology CrossRef
8. Vesical clear cell adenocarcinoma of Müllerian origin treated conservatively with partial cystectomy
   Justin A Harold et al, 2022, BMJ Case Reports CrossRef
9. Cadherin-16 (CDH16) immunohistochemistry: a useful diagnostic tool for renal cell carcinoma and papillary carcinomas of the thyroid
   Maximilian Lennartz et al, 2023, Scientific Reports CrossRef
10. Oncogenes in high grade serous adenocarcinoma of the ovary
    Pacharla Manasa et al, 2020, Genes & Cancer CrossRef
11. PAX8, an Emerging Player in Ovarian Cancer
    Priyanka Gokulnath et al, 2021, Ovarian Cancer: Molecular & Diagnostic Imaging and Treatment Strategies CrossRef
12. PAX8 in the Junction between Development and Tumorigenesis
    Reli Rachel Kakun et al, 2022, International Journal of Molecular Sciences CrossRef
13. PAX8 as a Potential Target for Ovarian Cancer: What We Know so Far
    Tina Di Palma et al, 2022, OncoTargets and Therapy CrossRef